Published in JAMA Dermatol on February 01, 2013
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index | NCT00879944
Excess adiposity preceding pediatric psoriasis. JAMA Dermatol (2014) 0.91
Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne) (2015) 0.87
Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis: A Nested Case-Control Study. JAMA Dermatol (2016) 0.81
Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. Front Immunol (2014) 0.80
Correlation between psoriasis' severity and waist-to-height ratio. An Bras Dermatol (2014) 0.78
Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs (2015) 0.78
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol (2016) 0.77
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. J Invest Dermatol (2016) 0.75
Psoriatic plaques "koebnerizing" to areas of acanthosis nigricans in an obese female: clues to a common pathway? J Clin Aesthet Dermatol (2014) 0.75
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA (2006) 72.59
2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 (2002) 38.37
Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA (2012) 28.69
The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics (1999) 11.20
Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med (1992) 10.44
Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 9.42
Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr (2004) 8.87
Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr (2010) 8.71
Preventing childhood obesity: health in the balance: executive summary. J Am Diet Assoc (2005) 7.91
Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr (2004) 7.08
Assessment of child and adolescent overweight and obesity. Pediatrics (2007) 6.02
Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. Am J Clin Nutr (2002) 4.68
Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med (2002) 4.47
Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 4.12
Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev (2011) 4.07
Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index. Int J Obes Relat Metab Disord (2000) 3.65
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol (2005) 3.11
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol (2008) 2.95
Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med (2007) 2.89
A population-based comparison of BMI percentiles and waist-to-height ratio for identifying cardiovascular risk in youth. J Pediatr (2005) 2.59
Comparison of the WHO child growth standards and the CDC 2000 growth charts. J Nutr (2007) 2.57
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol (2010) 2.29
Changes in state-specific childhood obesity and overweight prevalence in the United States from 2003 to 2007. Arch Pediatr Adolesc Med (2010) 2.20
Waist circumference for the screening of the metabolic syndrome in children. Acta Paediatr (2002) 2.19
Obesity predisposes to Th17 bias. Eur J Immunol (2009) 2.04
Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol (2009) 2.01
Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics (2004) 2.01
Waist circumference and cardiovascular risk factors in prepubertal children. Obes Res (2001) 1.89
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol (2004) 1.82
Waist to stature ratio is more strongly associated with cardiovascular risk factors than other simple anthropometric indices. Ann Epidemiol (2003) 1.70
Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics (2009) 1.70
Waist-to-height ratio is the best predictor of cardiovascular disease risk factors in Japanese schoolchildren. J Atheroscler Thromb (2002) 1.70
Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic americans. Ann Epidemiol (2000) 1.63
The epidemiology of bilateral slipped capital femoral epiphysis. A study of children in Michigan. J Bone Joint Surg Am (1993) 1.36
Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol (2007) 1.33
Epidemiology and comorbidity of psoriasis in children. Br J Dermatol (2009) 1.27
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res (2008) 1.27
Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg (2004) 1.24
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr (2008) 1.21
Blount disease (tibia vara): another skeletal disorder associated with childhood obesity. J Pediatr (1982) 1.19
A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol (2000) 1.18
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol (2007) 1.14
Predictive associations between alternative measures of childhood adiposity and adult cardio-metabolic health. Int J Obes (Lond) (2010) 1.13
Developing waist-to-height ratio cut-offs to define overweight and obesity in children and adolescents. Public Health Nutr (2010) 1.13
Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med (2008) 1.10
Obesity in Malaysia. Obes Rev (2002) 1.09
Remission of psoriasis after open gastric bypass. Obes Surg (2006) 1.06
Obesity increases metabolic syndrome risk factors in school-aged children from an urban school in Mexico city. J Am Diet Assoc (2007) 1.05
Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol (2009) 1.05
Utility of waist circumference percentile for risk evaluation in obese children. Int J Pediatr Obes (2010) 0.99
BMI percentile curves for Chinese children aged 7-18 years, in comparison with the WHO and the US Centers for Disease Control and Prevention references. Public Health Nutr (2010) 0.92
The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr (2011) 0.89
Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol (2008) 0.87
Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol (2010) 0.82
A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol (2010) 0.80
Overweight and childhood psoriasis. Br J Dermatol (2009) 0.77
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer (2012) 2.29
The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol (2007) 2.17
Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch Toxicol (2014) 2.13
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs (2014) 1.99
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol (2006) 1.77
Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2013) 1.75
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 1.72
Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol (2003) 1.69
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr (2010) 1.67
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges (2010) 1.60
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol (2003) 1.60
"Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak. Pediatrics (2013) 1.57
Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol (2005) 1.54
Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. J Am Acad Dermatol (2004) 1.53
Cardiocutaneous syndromes and associations. J Am Acad Dermatol (2002) 1.53
Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol (2012) 1.51
High-resolution manometry correlates of ineffective esophageal motility. Am J Gastroenterol (2012) 1.47
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol (2011) 1.44
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2002) 1.44
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol (2003) 1.43
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Annular lichenoid dermatitis of youth. J Am Acad Dermatol (2003) 1.40
A comparative study of pulsed 532-nm potassium titanyl phosphate laser and electrocoagulation in the treatment of spider nevi. Dermatol Surg (2010) 1.40
Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol (2006) 1.40
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol (2012) 1.40
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed (2005) 1.39
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol (2013) 1.32
Subcutaneous sarcoidosis: report of two cases and review of the literature. Clin Rheumatol (2011) 1.29
Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol (2008) 1.28
The use of cyclosporine in dermatology: part I. J Am Acad Dermatol (2010) 1.26
Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol (2007) 1.26
Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J (2002) 1.24
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol (2005) 1.23
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
The role of chemokines in allergic contact dermatitis. Arch Dermatol Res (2002) 1.22
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr (2008) 1.21
Comorbidities in psoriasis patients. Semin Cutan Med Surg (2010) 1.21
Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost (2009) 1.21
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med (2015) 1.20
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol (2007) 1.17
Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis (2003) 1.16
Drug-induced lupus erythematosus. Arch Dermatol Res (2008) 1.16
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (2008) 1.15
Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol (2010) 1.12
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail (2012) 1.11
The efficacy of pulsed dye laser treatment for inflammatory skin diseases: a systematic review. J Am Acad Dermatol (2013) 1.10
EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol (2009) 1.09
STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J (2010) 1.09
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol (2003) 1.09
Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol (2010) 1.09
Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol (2003) 1.09
Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood (2002) 1.08
Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy (2005) 1.08
The use of cyclosporine in dermatology: part II. J Am Acad Dermatol (2010) 1.07
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology (2008) 1.06
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail (2012) 1.06
Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol (2009) 1.06
Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther (2003) 1.04
Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol (2004) 1.03
Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol (2005) 1.03
The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) (2012) 1.02
Update on botulinum toxin for facial aesthetics. Dermatol Clin (2002) 1.01
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol (2005) 1.01
Trials of Intervention Principles: Evaluation Methods for Evolving Behavioral Intervention Technologies. J Med Internet Res (2015) 1.01
Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol (2002) 1.00
Characterization of the biological activities of uridine diphosphate in human dendritic cells: Influence on chemotaxis and CXCL8 release. J Cell Physiol (2004) 0.99
Erythema nodosum: etiological factors and relapses in a retrospective cohort study. Eur J Dermatol (2010) 0.99
Chemokine networks in inflammatory skin diseases. Eur J Dermatol (2004) 0.98
Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol (2013) 0.98
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail (2012) 0.98
Canine models of atopic dermatitis: a useful tool with untapped potential. J Invest Dermatol (2009) 0.98
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail (2012) 0.97